The role of thrombin-activatable fibrinolysis inhibitor in the pathophysiology of hemostasis

Advances in Clinical and Experimental Medicine

Volumn 19, Issue 3, 2010, Pages 379-387

  Joanna, Dubis ^a   Wojciech, Witkiewicz ^a  

^a REGIONAL SPECIALIST HOSPITAL   (Poland)

Author keywords

Hemostasis; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

BLOOD CLOTTING; ENZYME ACTIVITY; ENZYME STRUCTURE; FIBRINOLYSIS; GENETIC POLYMORPHISM; HEMOSTASIS; HUMAN; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW;

EID: 77954892951     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Zorio E, Gilbert-Estellés J, España F, Ramón LA, Cosín R, Estellés A: Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008, 5, 923-929. (Pubitemid 351736413)
2. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL: The cell biology of the plasminogen system. FASEB J 1995, 9, 939-945.
3. Fleury V, Anglés-Cano E: Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991, 30, 7630-7638.
4. Mosnier LO, Meijers JC, Bouma BN: Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001, 85, 5-11.
5. Wang YX, da Cunha V, Vincelette J, Zhao L, Nagashima M, Kawai K, Yuan S, Emayan K, Islam I, Hosoya J, Sullivan ME, Dole WP, Morser J, Buckman BO, Vergona R: A novel inhibitor of activated thrombin activatable fibrinolysis inhibitor (TAFIa) - part II: enhancement of both exogenous and endogenous fibrinolysis in animal models of thrombosis. Thromb Haemost 2007, 97, 54-61. (Pubitemid 46242387)
6. Bajzar L, Manuel R, Nesheim ME: Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995, 270, 14477-14484.
7. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JC, Bouma BN: Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003, 101, 4844-4846. (Pubitemid 36857744)
8. Campbell WD, Lazoura E, Okada N, Okada H: Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002, 46, 131-134. (Pubitemid 34194973)
9. Tilburg NH, Rosendaal FR, Bertina RM: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95, 2855-2859. (Pubitemid 30235895)
10. Tregouet DA, Schnabel R, Alessi MC, Godefroy T, Declerck PJ, Nicaud V, Munzel T, Bickel C, Rupprecht HJ, Lubos E, Zeller T, Juhan-Vague I, Blankenberg S, Tiret L, Morange PE: AtheroGene Investigators. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol 2002, 22, 867-873.
11. Watanabe R, Wada H, Watanabe Y, Sakakura M, Nakasaki T, Mori Y, Nishikawa M, Gabazza EC, Nobori T, Shiku H: Activity and antigen levels of thrombin-activatable fibrinolysis inhibitor in plasma of patients with disseminated intravascular coagulation. Thromb Res 2001, 104, 1-6. (Pubitemid 32918249)
12. Bajzar L, Morser J, Nesheim M: TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996, 271, 16603-16608. (Pubitemid 26239017)
13. Bouma BN, Meijers JC: Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U) Thromb Haemost 2003, 1, 1566-1574.
14. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M: Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002, 11, 277, 1021-1030. (Pubitemid 34968847)
15. Boffa MB, Bell R, Stevens WK, Nesheim ME: Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000, 275, 12868-12878. (Pubitemid 30241442)
16. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 2007, 82, 1010-1012. (Pubitemid 350004393)
17. Campbell W, Okada H: An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunits. Biochem Biophys Res Commun 1989, 162, 933-939. (Pubitemid 19214673)
18. Mutch NJ, Moore NR, Wang E, Booth NA: Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003, 1, 2000-2007.
19. Mosnier LO, Bouma BN: Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006, 26, 2445-2453.
20. Colucci M, Cattaneo M, Martinelli I, Semeraro F, Binetti BM, Semeraro N: Mild hyperhomocysteinemia is associated with increased TAFI levels and reduced plasma fibrinolytic potential. J Thromb Haemost 2008, 6, 1571-1577.
21. Lorand L: Sol Sherry Lecture in Thrombosis: research on clot stabilization provides clues for improving thrombolytic therapies. 1: Arterioscler Thromb Vasc Biol 2000, 20, 2-9.
22. Vairaktaris E, Yapijakis C, Nkenke E, Vassiliou S, Vylliotis A, Nixon AM, Derka S, Ragos V, Spyridonidou S, Tsigris C, Neukam FW, Patsouris E: The 1040C/T polymorphism influencing thermal stability and activity of thrombin activatable fibrinolysis inhibitor is associated with risk for oral cancer. Am J Hematol 2007, 82, 1010-1012 (Pubitemid 350004393)
23. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I: Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001, 97, 2053-2058. (Pubitemid 32239086)
24. Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferneres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I: The Prime Study Group. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost 2005, 3, 1503-1510. (Pubitemid 41725210)
25. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR: The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006, 134, 92-94. (Pubitemid 43830033)
26. Akatsu H, Ishiguro M, Ogawa N, Kanesaka T, Okada N, Yamamoto T, Campbell W, Okada H: Plasma levels of unactivated thrombin activatable fibrinolysis inhibitor (TAFI) are down-regulated in young adult women: analysis of a normal Japanese population. Microbiol Immunol 2007, 51, 507-517. (Pubitemid 46799718)
27. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL: Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem 2003, 278, 51059-51067. (Pubitemid 38020340)
28. Boffa MB, Hamill JD, Maret D, Brown D, Scott ML, Nesheim ME, Koschinsky MLJ: Acute Phase Mediators Modulate Thrombin-activable Fibrinolysis Inhibitor (TAFI) Gene Expression in HepG2 Cells. Biol Chem 2003, 278, 9250-9257. (Pubitemid 36800408)
29. Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A: Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 2003, 122(6), 958-965.
30. Okumura N, Koh T, Hasebe Y, Seki T, Ariga T: A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture. J Biol Chem 2009, 284, 16553-16561.
31. Donmez A, Aksu K, Celik HA, Keser G, Cagirgan S, Omay SB, Inal V, Aydin HH, Tombuloglu M, Doganavsargil E: Thrombin activatable fibrinolysis inhibitor in Behçet's disease. Thromb Res 2005, 115, 287-292.
32. Koutroubakis IE, Sfiridaki A, Tsiolakidou G, Coucoutsi C, Theodoropoulou A, Kouroumalis EA: Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008, 20, 912-916.
33. Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S: Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients. Endocr J 2007, 54, 593-599.
34. Gresele P, Binetti BM, Branca G, Clerici C, Asciutti S, Morelli A, Semeraro N, Colucci M: TAFI deficiency in liver cirrhosis: relation with plasma fibrinolysis and survival. Thromb Res 2008, 121, 763-768.
35. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, Kohler HP: Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 2002, 88, 1020-1025.
36. Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J: Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2000, 34, 1038-1040.
37. Franco RF, Reitsma PH: Genetic risk factors of venous thrombosis. Hum Genet 2001, 109, 369-384.
38. Wang X, Smith PL, Hsu MY, Tamasi JA, Bird E, Schumacher WA: Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J Thromb Thrombolysis 2007, 23, 41-49.
39. Ricart JM, Ramón LA, Vayá A, España F, Santaolaria ML, Todolí J, Castelló R, Fontcuberta J, Estellés A: Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis. Br J Haematol 2008, 141, 716-719.
40. Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A: Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. 1: J Thromb Haemost 2008, 6, 268-276.
41. Letai A, Kuter DJ: Cancer, coagulation, and anticoagulation. Oncologist 1999, 4, 443-449.
42. Reijerkerk A, Meijers JC, Havik SR, Bouma BN, Voest EE, Gebbink MF: Tumor growth and metastasis are not affected in thrombin-activatable fibrinolysis inhibitor-deficient mice. J Thromb Haemost 2004, 2, 769-779.
43. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, Nishii Y, Hayashi T, Suzuki K, Adachi Y: Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004, 76, 214-219.
44. Koldas M, Gummus M, Seker M, Seval H, Hulya K, Dane F, Kural A, Gumus A, Salepci T, Turhal NS: Thrombin-activatable fibrinolysis inhibitor levels in patients with non-small-cell lung cancer. Clin Lung Cancer 2008, 9, 112-115.
45. Meijers JC, Oudijk EJ, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, Fijnheer R: Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000, 108, 518-523.
46. Lansberg MG, Bluhmki E, Thijs VN: Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009, 40, 2438-2441.